SCHEMBL20522281

SCHEMBL20522281

COC(=O)CCCNS(=O)(=O)c1ccc(F)cc1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.71
ALDH1A1 P00352 7/20 0.64
PKM P14618 3/20 0.64
MEN1 O00255 1/20 0.64
KMT2A Q03164 1/20 0.64
CA12 O43570 1/20 0.53
CA2 P00918 1/20 0.53
CA7 P43166 1/20 0.53
CA9 Q16790 1/20 0.53
CA14 Q9ULX7 1/20 0.53
HDAC3 O15379 2/20 0.50
HDAC1 Q13547 2/20 0.50
CYP2C19 P33261 2/20 0.50
SMN1; SMN2 Q16637 2/20 0.50
CYP1A2 P05177 1/20 0.50
POLB P06746 1/20 0.50
CYP2D6 P10635 1/20 0.50
TDP1 Q9NUW8 1/20 0.50
CYP2C9 P11712 1/20 0.50
KDM4E B2RXH2 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2631178 0.94 ALDH1A1 (0.69) LMNAALDH1A1PKMMEN1KMT2A
SCHEMBL28399402 0.87 ALDH1A1 (0.65) LMNAALDH1A1PKMMEN1KMT2A
SCHEMBL14093752 0.85 ALDH1A1 (0.64) LMNAALDH1A1PKMMEN1KMT2A
SCHEMBL7945710 0.85 ALDH1A1 (0.64) LMNAALDH1A1PKMMEN1KMT2A
SCHEMBL28147718 0.85 ALDH1A1 (0.71) LMNAALDH1A1PKMCA12CA7
SCHEMBL4712869 0.83 ALDH1A1 (0.61) LMNAALDH1A1PKMMEN1KMT2A
SCHEMBL12570978 0.83 ALDH1A1 (0.68) LMNAALDH1A1PKMHDAC1SMN1; SMN2
SCHEMBL4712224 0.82 ALDH1A1 (0.60) LMNAALDH1A1PKMCYP2C19SMN1; SMN2
SCHEMBL14093751 0.82 ALDH1A1 (0.60) LMNAALDH1A1PKMMEN1KMT2A
SCHEMBL13223680 0.81 ALDH1A1 (0.69) LMNAALDH1A1PKMCA12CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12384772-B2 Inhibitors VIVORYON THERAPEUTICS N.V. (DE) 2025-08-12 US disclosed
CN-117024352-A Novel inhibitors 维沃里翁治疗股份有限公司 2023-11-10 CN disclosed
CN-110719910-B Novel inhibitors 维沃里翁治疗股份有限公司 2023-07-21 CN disclosed
US-20220274977-A1 NOVEL INHIBITORS VIVORYON THERAPEUTICS N.V. (DE) 2022-09-01 US disclosed
US-11339152-B2 Inhibitors VIVORYON THERAPEUTICS N.V. 2022-05-24 US disclosed
US-11339152-B2 Inhibitors VIVORYON THERAPEUTICS N.V. 2022-05-24 US disclosed
US-20200377493-A1 NOVEL INHIBITORS VIVORYON THERAPEUTICS N.V. (DE) 2020-12-03 US disclosed
US-20200377493-A1 NOVEL INHIBITORS VIVORYON THERAPEUTICS N.V. (DE) 2020-12-03 US disclosed
EP-3601269-A1 NOVEL INHIBITORS Probiodrug AG (DE) 2020-02-05 EP disclosed
CN-110719910-A Novel inhibitors 前体生物药物股份公司 2020-01-21 CN disclosed
WO-2018178384-A1 NOVEL INHIBITORS PROBIODRUG AG (DE) 2018-10-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200377493-A1 NOVEL INHIBITORS GLUL, GLS, QPCT LMNA 3291/4885ALDH1A1 1681/4885PKM 1434/4885
US-11339152-B2 Inhibitors GLUL, QPCT, GLS LMNA 3155/4885ALDH1A1 1490/4885PKM 1481/4885
US-12384772-B2 Inhibitors GLS, QPCT, GLS2 LMNA 3549/4885ALDH1A1 1415/4885PKM 1292/4885
US-20220274977-A1 NOVEL INHIBITORS GLUL, GLS, QPCT LMNA 3650/4885ALDH1A1 1184/4885PKM 1601/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.